Highlights
- Long-term levothyroxine supplementation (≥5 years) is associated with an 18% reduction in major cardiovascular events in adults over 50.
- All-cause mortality was significantly lower (aHR 0.71) in treated individuals compared to untreated controls over a 10-year follow-up.
- Clinical benefits are strictly localized to patients whose TSH levels exceed age-specific reference intervals, rather than standard laboratory ranges.
- Extensive inverse probability of treatment weighting (IPTW) analysis confirms no significant increase in bone-related adverse events, such as fragility fractures.
Background
Subclinical hypothyroidism (SCH), characterized by elevated serum thyrotropin (TSH) levels despite normal free thyroxine (fT4) concentrations, is a common finding in the aging population. Data suggests that up to 10–15% of adults over the age of 65 may meet the biochemical criteria for SCH. However, a major clinical conundrum persists: Does the physiological rise in TSH observed with advancing age represent a compensatory, perhaps even protective, adaptation, or is it a manifestation of early thyroid failure that warrants intervention?
For years, international guidelines have remained cautious. The concern has been two-fold: first, that treating the elderly for what may be a normal aging process leads to unnecessary medicalization; and second, that levothyroxine therapy—particularly if it leads to over-replacement—might induce iatrogenic atrial fibrillation or accelerate bone mineral density loss. Conversely, untreated SCH has been mechanistically linked to atherosclerosis, diastolic dysfunction, and hypercholesterolemia. The ACEL-UK-ETT (Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing UK Population with Subclinical Hypothyroidism: Emulated Target Trial) was designed to provide clarity in this space by utilizing robust real-world data and advanced causal inference methods.
Key Content
Methodological Innovation: The Emulated Target Trial
Traditional observational studies often suffer from immortal time bias and selection bias. The ACEL-UK-ETT addressed these limitations by using an “Emulated Target Trial” design. Leveraging data from The Health Improvement Network (THIN)—a large UK primary care database—the researchers identified 22,621 patients aged 50 and older with SCH (TSH 4.1-10.0 mU/L).
The study utilized Inverse Probability of Treatment Weighting (IPTW) to balance the treated and untreated cohorts across a range of covariates, including age, sex, BMI, comorbidities (via the Charlson Comorbidity Index), baseline cholesterol, hypertension status, and smoking history. This approach mimics the rigor of a randomized controlled trial (RCT) while capturing the long-term longitudinal outcomes (up to 10 years) that are often unfeasible in traditional prospective RCTs.
Cardiovascular and Survival Outcomes
The primary finding of the study was a significant reduction in major adverse cardiovascular events (MACE), which included myocardial infarction, angina, stroke, peripheral vascular disease, and stent procedures. The IPTW-adjusted hazard ratio (aHR) was 0.82 (95% CI: 0.74-0.91), representing an 18% relative risk reduction.
Even more striking was the impact on all-cause mortality, with an aHR of 0.71 (95% CI: 0.67-0.75). These findings suggest that the metabolic and hemodynamic benefits of achieving euthyroidism in this population translate into substantial survival advantages. However, a critical caveat emerged: these benefits were not immediate. The reduction in cardiovascular risk was only statistically significant after at least five years of consistent levothyroxine therapy, underscoring the importance of long-term management in chronic endocrine disorders.
Safety Profile: Bone Health and Iatrogenic Risks
A perennial concern in geriatric endocrinology is the risk of levothyroxine-induced thyrotoxicosis leading to osteoporosis. The ACEL-UK-ETT specifically tracked secondary outcomes related to bone health, including fragility fractures and new diagnoses of osteoporosis. The analysis yielded an aHR of 1.04 (95% CI: 0.93-1.17, p = 0.45), indicating that levothyroxine use, when managed within primary care settings for SCH, does not significantly increase the risk of skeletal compromise. This provides a reassuring safety margin for clinicians who have previously hesitated to initiate therapy in older patients.
The Shift to Age-Specific TSH Interpretation
Perhaps the most transformative aspect of this study is the subgroup analysis regarding age-specific TSH levels. The researchers found that cardiovascular benefits were predominantly seen in patients whose TSH was elevated *relative to their age group*, rather than just exceeding the standard laboratory cutoff of 4.0 or 4.5 mU/L.
For example, if a 75-year-old has a TSH of 5.5 mU/L, this might be within the normal range for their age, and the study suggests they may not benefit from treatment. However, if that same patient has a TSH of 8.0 mU/L (exceeding the 95th percentile for their age), the reduction in cardiovascular risk becomes pronounced. This finding advocates for a more nuanced, personalized approach to thyroid diagnostics in the elderly.
Expert Commentary
The ACEL-UK-ETT results represent a significant departure from some earlier trials, such as the TRUST trial, which found no benefit of levothyroxine in older adults. The divergence can likely be attributed to two factors: follow-up duration and the use of age-specific thresholds. The TRUST trial follow-up was relatively short (median 1.2 years), whereas the ACEL-UK-ETT demonstrated that cardiovascular protection requires sustained therapy over a five-year horizon.
From a mechanistic perspective, the benefits likely stem from the correction of subclinical hypothyroidism’s adverse effects on the vascular system. SCH is known to increase systemic vascular resistance and impair endothelial-dependent vasodilation. By restoring thyroxine levels, levothyroxine may improve myocardial contractility and lipid profiles, thereby slowing the progression of atherosclerosis.
However, clinicians must remain vigilant against “over-treatment.” The study results do not give a green light for indiscriminate levothyroxine use. Instead, they reinforce the need for a targeted strategy: identify those with truly pathological TSH elevations (above age-specific norms), initiate therapy judiciously, and maintain long-term follow-up to ensure patients remain within the target range.
Conclusion
The ACEL-UK-ETT trial provides robust evidence that levothyroxine therapy is both safe and effective for reducing cardiovascular morbidity and all-cause mortality in an aging population with subclinical hypothyroidism. By employing the emulated target trial methodology, the study offers a bridge between observational evidence and clinical practice.
The primary practical implication for clinicians is the adoption of age-specific TSH reference ranges. Treatment should be prioritized for patients whose thyrotropin levels exceed these tailored thresholds, with the expectation that clinical benefits—particularly cardiovascular protection—will manifest over a long-term (5-10 year) treatment window. Future research should focus on refining these age-specific intervals across diverse global populations to further standardize geriatric thyroid care.
References
- Holley M, Razvi S, Maxwell I, Dew R, Wilkes S. Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing UK Population with Subclinical Hypothyroidism: Emulated Target Trial (ACEL-UK-ETT). Thyroid. 2026;36(3):242-250. PMID: 41712269.
- Stott DJ, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. PMID: 28402245.
- Razvi S, et al. Subclinical Hypothyroidism: Vaccine for Cardiovascular Disease? European Heart Journal. 2018;39(24):2304-2306.
